Navigation Links
Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
Date:1/12/2009

HAMILTON, Bermuda and CORONA, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Warner Chilcott Limited (Nasdaq: WCRX) announced today that they have entered into Settlement and License Agreements to resolve pending patent litigation related to Warner Chilcott's oral contraceptive products, Loestrin(R) 24 and Femcon(R) Fe. Separately, Warner Chilcott and Watson have entered into a Co-Promotion Agreement relating to Warner Chilcott's Femring(R) product and License and Supply Agreements relating to a Warner Chilcott development-stage oral contraceptive product.

Loestrin(R) 24 and Femcon(R) Fe Settlement and License Agreements

Under the terms of the settlement agreements, Warner Chilcott has granted Watson a non-exclusive license to the U.S. patents covering Loestrin(R) 24 Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets) and Femcon(R) Fe (norethindrone, ethinyl estradiol tablets, chewable, ferrous fumarate tablets). The agreement covering Loestrin(R) 24 Fe will permit Watson to commence marketing its generic equivalent product on the earlier of January 22, 2014 or the date on which another generic version of Loestrin(R) 24 Fe enters the U.S. market. The agreement covering Femcon(R) Fe will permit Watson to commence marketing its generic equivalent product on the earlier of 180 days after Barr Laboratories, Inc. (now Teva Pharmaceutical Industries, Ltd.) enters the market with a generic equivalent product, or January 1, 2013. The parties will promptly file dismissals without prejudice that will conclude both litigations. Additional details concerning the settlements have not been disclosed.

Co-Promotion Agreement


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.; Warner Chilcott Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Virginia Faith Leaders Call on Senators Webb & Warner to Cosponsor Legislation to Protect Kids from Tobacco
2. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
3. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007
4. Warner Chilcott to Present at the 26th Annual JPMorgan Healthcare Conference
5. Warner Chilcott to Present at the 2008 Wachovia Healthcare Conference
6. Warner Chilcott Announces 2008 Financial Guidance
7. Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director
8. Sharing Miracles Television Program to Feature Mountain Climber and Cancer Survivor Sean Swarner
9. CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecoms IP VPN
10. LodgeNet Appoints John E. Haire, Former Time Warner Executive, to Board of Directors
11. Warner Chilcott Announces Settlement of Securities Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- Pigs, hearts transplanted into baboons survived for more ... previously achieved, researchers report. The work is part ... to shorten transplant waiting lists. In this study, ... abdomens. The genetic engineering and new methods of suppressing ... hearts to survive for more than a year. ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... been an option, but a new study shows that only ... common reasons women didn,t undergo reconstruction was that they felt ... they were focused on their cancer treatment," said lead researcher ... Kettering Cancer Center, in New York City. Also common ...
(Date:8/20/2014)... to spawning grounds through fast-moving waters may be at ... scientists. , When salmon encounter turbulent, fast-moving water ... they must move upstream using a behaviour known as ... , "Days after sockeye passed through extremely fast-moving water, ... distance from their spawning grounds," said Nicholas Burnett, a ...
(Date:8/20/2014)... NEW YORK -- The most common cause of endophthalmitis, ... trauma, eye surgery, and eye injections, are the well-known ... bacterial strains, according to a study published in the ... a review of 25 years of cases at New ... , The new study found that gram-positive bacteria, ...
(Date:8/20/2014)... HealthDay Reporter TUESDAY, Aug. 19, 2014 ... baby,s immune system is twice as common as once believed, ... This is the first evaluation of the effect of ... severe combined immunodeficiency (SCID), or "Bubble Boy" disease, the researchers ... the boy in the bubble, who was born without an ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3
... Pakistan Tuesday enhanced their cooperation in the crucial area ... polio and avian flu. // ,"The ... exchanged ideas on management of avian influenza," external affairs ... the first meeting of the India-Pakistan Joint Commission technical-level ...
... over reports of malarial deaths in Jharkhand's Sahibganj district, the ... // , today urged the health department to step up ... at the earliest direct its medical teams to find out ... disease has afflicted several people in the district, JD(U) spokesman ...
... A recent study has revealed that the place of birth determines ... far lower life expectancy than those born in south east England ... city was found to be 69.3 it was found to be ... conducted the research and it has ranked the 10 best and ...
... insisted that hospital consultants who are not referring patients to ... concerns that the NTPF has only seen a fraction of ... ,NTPF chairman Pat O'Byrne commented that there was no ... months for a surgical procedure. ,"There's no doubt ...
... Boards (DHBs), striking junior doctors returned to hospital calling off their ... doctor's union - Resident Doctors' Association (RDA) and the DHBs met ... planned to meet on Thursday for confirming the results. ... lasted for 5 days. , ,But unfortunately last time ...
... Carolina have found that very few of the patients ... resulted due to chronic obstructive pulmonary disease (COPD) such ... and management. ,Explaining that ideal care means ... the treatment guidelines for this condition and none of ...
Cached Medicine News:Health News:Life Expectancy Determined by Place of Birth 2Health News:COPD Patients In US Are Not Receiving 'Ideal Care' 2
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
(Date:8/20/2014)... 2014 Trovagene, Inc. (NASDAQ:   TROV), a ... from two clinical studies will be presented at the ... diagnostic test for the detection of high risk strains ... to take place in Seattle ... Additionally, a new U.S. patent was issued earlier this ...
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... announces that a new market research report is ... Degeneration Therapy Area Pipeline Report ... Therapy Area Pipeline Report contains detailed information on ... insight into the pipeline status of macular degeneration ...
... Allscripts (NASDAQ: MDRX ) announced today that it ... March 31, 2011 after the stock market closes on Thursday, ... and webcast to discuss the company,s earnings and other information ... (Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO ) More ...
Cached Medicine Technology:Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 2Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 2Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: